Variables | Univariate Analyses | Multivariate Analysis | ||||
---|---|---|---|---|---|---|
OR | 95%CI | P-value | OR | 95%CI | P-value | |
Mutation site at initial diagnosis; Exon 19 Deletion vs. L858R | 0.17 | 0.05–0.51 | 0.002 | 0.04 | 0.004–0.34 | 0.003 |
Reason for termination of TKIs; | 2.26 | 1.25–4.11 | 0.007 | 3.65 | 1.39–9.59 | 0.008 |
Ongoing | Reference | Reference | ||||
AEs | 1 | – | – | 1 | – | – |
Tumor growth | 37.3 | 3.30–421.6 | 0.003 | 33.8 | 1.60–713.3 | 0.024 |
New lesions | 12.4 | 1.32–117.0 | 0.027 | 44.9 | 2.13–950.9 | 0.014 |
Medical Drugs at TKI-naïve line | 0.24 | 0.08–0.72 | 0.01 | 0.09 | 0.01–0.62 | 0.014 |
Gefitinib | Reference | Reference | ||||
Erlotinib | 0.18 | 0.035–0.95 | 0.044 | 0.49 | 0.02–0.99 | 0.049 |
Afatinib | 0.06 | 0.007–0.55 | 0.012 | 0.01 | 0.0002–0.53 | 0.02 |
Chemotherapy; absent vs. present | 2.63 | 0.84–8.22 | 0.09 | NI | ||
“Serum level of CEA at progression” divided by “Serum nadir level of CEA” | 1.16 | 0.97–1.39 | 0.11 | 1.22 | 0.77–1.93 | 0.4 |
Serum nadir level of CEA (ng/mL) | 0.97 | 0.95–1.01 | 0.14 | NI |